SHShigeki Hibi

Shigeki Hibi

*This is an algorithmically generated author record based on publicly available information.

Shigeki Hibi has a total of 5 co-authors. Here are the top co-authors by number of shared publications:

  • Hiroyuki Yoshimura

    Tsukuba Basic Research Laboratories, Eisai Co., Ltd., 1-3, Tokodai 5-chome, Tsukuba-shi, Ibaraki, 300-26, Japan

    1 shared publication
  • Kenji Tai

    Tsukuba Basic Research Laboratories, Eisai Co., Ltd., 1-3, Tokodai 5-chome, Tsukuba-shi, Ibaraki, 300-26, Japan

    1 shared publication
  • Kouichi Kikuchi

    Tsukuba Basic Research Laboratories, Eisai Co., Ltd., 1-3, Tokodai 5-chome, Tsukuba-shi, Ibaraki, 300-26, Japan

    1 shared publication
  • Mitsuo Nagai

    Tsukuba Basic Research Laboratories, Eisai Co., Ltd., 1-3, Tokodai 5-chome, Tsukuba-shi, Ibaraki, 300-26, Japan

    1 shared publication
  • Takayuki Hida

    Tsukuba Basic Research Laboratories, Eisai Co., Ltd., 1-3, Tokodai 5-chome, Tsukuba-shi, Ibaraki, 300-26, Japan

    1 shared publication

Latest Publications

  • Syntheses and Structure−Activity Relationships of Novel Retinoid X Receptor Agonists

    by Shigeki Hibi, Kouichi Kikuchi, Hiroyuki Yoshimura, Mitsuo Nagai, Kenji Tai, Takayuki Hida

    As part of our studies to develop novel retinoids with increased affinity and selectivity for the retinoid X receptor (RXR) subfamily, we have designed and synthesized a series of (E,E,E)-7-(1,2,3, 4-tetrahydroquinolin-6-yl)-7-alkyl-6-fluoro-3-methylhepta-2, 4, 6-trienoic acid derivatives. These tetrahydroquinolines, generated by introducing a polar N atom into the hydrophobic part of the retinoid skeleton, showed high binding affinity to RXRs. Addition of fluorine at the 6-position of the 2,4,6-trienoic acid moiety afforded compounds which elicit potent and selective transactivation of the RXRs. Compound 14b (ER-35794), which possesses an ethyl substituent at the 7-position and fluorine at the 6-position of the triene moiety, is one of the most potent and selective RXR agonists reported to date.